JP2023120208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023120208A5 JP2023120208A5 JP2023085796A JP2023085796A JP2023120208A5 JP 2023120208 A5 JP2023120208 A5 JP 2023120208A5 JP 2023085796 A JP2023085796 A JP 2023085796A JP 2023085796 A JP2023085796 A JP 2023085796A JP 2023120208 A5 JP2023120208 A5 JP 2023120208A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- modified polypeptide
- modified
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 108091005601 modified peptides Proteins 0.000 claims 12
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 4
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010000234 Abortion spontaneous Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000000995 spontaneous abortion Diseases 0.000 claims 2
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 1
- 208000033564 Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 101100434646 Mus musculus Alb gene Proteins 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 229960002773 hyaluronidase Drugs 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000015994 miscarriage Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025044077A JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531215P | 2017-07-11 | 2017-07-11 | |
| US62/531,215 | 2017-07-11 | ||
| PCT/US2018/041661 WO2019014360A1 (en) | 2017-07-11 | 2018-07-11 | POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF |
| JP2020500686A JP7684803B2 (ja) | 2017-07-11 | 2018-07-11 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500686A Division JP7684803B2 (ja) | 2017-07-11 | 2018-07-11 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044077A Division JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023120208A JP2023120208A (ja) | 2023-08-29 |
| JP2023120208A5 true JP2023120208A5 (enExample) | 2024-03-27 |
Family
ID=63036501
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500686A Active JP7684803B2 (ja) | 2017-07-11 | 2018-07-11 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2023085796A Pending JP2023120208A (ja) | 2017-07-11 | 2023-05-24 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2025044077A Pending JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500686A Active JP7684803B2 (ja) | 2017-07-11 | 2018-07-11 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044077A Pending JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11498960B2 (enExample) |
| EP (1) | EP3625265A1 (enExample) |
| JP (3) | JP7684803B2 (enExample) |
| KR (3) | KR102806328B1 (enExample) |
| CN (3) | CN117327188A (enExample) |
| AU (3) | AU2018301412B2 (enExample) |
| BR (1) | BR112019028269A2 (enExample) |
| CA (1) | CA3067247A1 (enExample) |
| CO (1) | CO2020000369A2 (enExample) |
| IL (3) | IL271920B2 (enExample) |
| MX (2) | MX2024005945A (enExample) |
| WO (1) | WO2019014360A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117327188A (zh) | 2017-07-11 | 2024-01-02 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| WO2020092546A1 (en) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| WO2020214679A1 (en) * | 2019-04-16 | 2020-10-22 | University Of Washington | Amantadine binding protein |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN114867484B (zh) | 2019-12-26 | 2024-08-06 | 卫材R&D管理有限公司 | 含有抑制补体c5的表达的双链核糖核酸的药物组合物 |
| WO2021144962A1 (ja) | 2020-01-17 | 2021-07-22 | オリンパス株式会社 | 発光装置、および駆動装置 |
| WO2021211940A1 (en) | 2020-04-16 | 2021-10-21 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| US20230357442A1 (en) * | 2020-10-05 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | Methods of treating dermatomyositis |
| TW202417490A (zh) * | 2022-08-31 | 2024-05-01 | 美商艾力克森製藥公司 | 用於治療鐮狀細胞病的融合多肽之劑量及投與 |
| CN116731149B (zh) * | 2023-06-07 | 2024-02-27 | 华中农业大学 | 草鱼补体活化分子碳末端肽C5a-CP及应用 |
| CN119241699B (zh) * | 2024-09-24 | 2025-11-28 | 广州康盛生物科技股份有限公司 | 一种抗人补体c5的单域抗体及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
| DK1355919T3 (da) * | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| AU2003286002B2 (en) * | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| AU2012254935B2 (en) * | 2004-02-12 | 2014-05-29 | Archemix Llc | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders |
| AU2005250216B2 (en) * | 2004-06-01 | 2009-12-10 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| CN100368022C (zh) | 2005-09-20 | 2008-02-13 | 中国人民解放军第二军医大学 | 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法 |
| BRPI0617688A2 (pt) * | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| SI2500030T2 (sl) | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni |
| ES2538114T3 (es) | 2008-03-03 | 2015-06-17 | Novelmed Therapeutics, Inc. | Anticuerpos anti-properdina |
| MX2011001371A (es) | 2008-08-05 | 2011-06-16 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5. |
| US20110002931A1 (en) * | 2009-06-23 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| CA2788993A1 (en) * | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| CA2811221C (en) | 2010-03-10 | 2018-01-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US9701742B2 (en) | 2011-07-01 | 2017-07-11 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| PE20150159A1 (es) | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
| AU2012362217A1 (en) | 2011-12-28 | 2014-07-24 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| RS58503B1 (sr) | 2012-02-20 | 2019-04-30 | Swedish Orphan Biovitrum Ab Publ | Polipeptidi koji se vezuju za humani komplement c5 |
| JP2015532303A (ja) | 2012-10-04 | 2015-11-09 | ノベルメド セラピューティクス，インコーポレーテッド | 溶血性疾患を治療するための補体第２経路特異的抗体 |
| MX367423B (es) | 2013-08-28 | 2019-08-21 | Affibody Ab | Polipeptidos de union a c5. |
| LT3038633T (lt) | 2013-08-28 | 2021-03-25 | Ipc Research, Llc | Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| MX2019008827A (es) | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| CN117327188A (zh) | 2017-07-11 | 2024-01-02 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
-
2018
- 2018-07-11 CN CN202311281139.3A patent/CN117327188A/zh active Pending
- 2018-07-11 BR BR112019028269-6A patent/BR112019028269A2/pt unknown
- 2018-07-11 IL IL271920A patent/IL271920B2/en unknown
- 2018-07-11 KR KR1020207002889A patent/KR102806328B1/ko active Active
- 2018-07-11 CA CA3067247A patent/CA3067247A1/en active Pending
- 2018-07-11 EP EP18746529.9A patent/EP3625265A1/en active Pending
- 2018-07-11 US US16/629,687 patent/US11498960B2/en active Active
- 2018-07-11 CN CN201880046102.3A patent/CN111201246B/zh active Active
- 2018-07-11 KR KR1020257014994A patent/KR20250068795A/ko active Pending
- 2018-07-11 CN CN202311281093.5A patent/CN117327187A/zh active Pending
- 2018-07-11 AU AU2018301412A patent/AU2018301412B2/en active Active
- 2018-07-11 WO PCT/US2018/041661 patent/WO2019014360A1/en not_active Ceased
- 2018-07-11 JP JP2020500686A patent/JP7684803B2/ja active Active
- 2018-07-11 KR KR1020257021037A patent/KR20250099285A/ko active Pending
-
2020
- 2020-01-08 MX MX2024005945A patent/MX2024005945A/es unknown
- 2020-01-08 MX MX2024005946A patent/MX2024005946A/es unknown
- 2020-01-15 CO CONC2020/0000369A patent/CO2020000369A2/es unknown
-
2022
- 2022-10-07 US US17/938,756 patent/US12221473B2/en active Active
-
2023
- 2023-05-24 JP JP2023085796A patent/JP2023120208A/ja active Pending
- 2023-09-21 IL IL307197A patent/IL307197B1/en unknown
-
2025
- 2025-01-02 US US19/007,782 patent/US20250163138A1/en active Pending
- 2025-01-16 AU AU2025200303A patent/AU2025200303A1/en active Pending
- 2025-01-16 AU AU2025200313A patent/AU2025200313A1/en active Pending
- 2025-03-18 JP JP2025044077A patent/JP2025118590A/ja active Pending
- 2025-10-21 IL IL324119A patent/IL324119A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023120208A5 (enExample) | ||
| JP2020532285A5 (enExample) | ||
| US11339210B2 (en) | Anti-C5 antibodies and methods of treating complement-related diseases | |
| CN112424224B (zh) | 抗白细胞介素-17a抗体、其药物组合物及其用途 | |
| JP2024063213A5 (enExample) | ||
| EP1751181B1 (en) | BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS | |
| KR101676269B1 (ko) | 인터루킨-13 결합 단백질 | |
| CN100503639C (zh) | 重组肿瘤特异性抗体及其应用 | |
| CN102741283B (zh) | 具有高阻断活性的抗-C5a结合部分 | |
| JP2014513953A5 (enExample) | ||
| WO2017015622A2 (en) | Gdf11 binding proteins and uses thereof | |
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| CN116249712A (zh) | Tau结合化合物 | |
| CN114380906B (zh) | 一种抗il-17a的单域抗体及其用途 | |
| CN118103395A (zh) | 泛特异性冠状病毒结合剂 | |
| CN101378781B (zh) | 制造免疫球蛋白的组合物和方法 | |
| TW201143789A (en) | Antigen binding proteins | |
| US20240101647A1 (en) | Sarbecovirus binders | |
| JP2020510416A (ja) | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 | |
| CN106795222A (zh) | 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法 | |
| CN119032105A (zh) | 松弛素或类似物的融合蛋白及其医药用途 | |
| CN116554324A (zh) | 一种特异性识别4-1bb的抗体、其制备方法及其用途 | |
| US12050189B2 (en) | Compositions and methods relating to structural determination of small proteins | |
| TW201019962A (en) | Ligands that have binding specificity for DC-SIGN | |
| CN117860786A (zh) | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 |